Genome-wide association study and polygenic risk scores of retinal thickness across the cognitive continuum: data from the NORFACE cohort.

Alzheimer’s disease (AD) GR@CE Genome-wide association study (GWAS) Mendelian randomization (MR) NORFACE Optical coherence tomography (OCT) Polygenic risk score (PRS)

Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
16 Feb 2024
Historique:
received: 01 07 2023
accepted: 26 01 2024
medline: 17 2 2024
pubmed: 17 2 2024
entrez: 16 2 2024
Statut: epublish

Résumé

Several studies have reported a relationship between retinal thickness and dementia. Therefore, optical coherence tomography (OCT) has been proposed as an early diagnosis method for Alzheimer's disease (AD). In this study, we performed a genome-wide association study (GWAS) aimed at identifying genes associated with retinal nerve fiber layer (RNFL) and ganglion cell inner plexiform layer (GCIPL) thickness assessed by OCT and exploring the relationships between the spectrum of cognitive decline (including AD and non-AD cases) and retinal thickness. RNFL and GCIPL thickness at the macula were determined using two different OCT devices (Triton and Maestro). These determinations were tested for association with common single nucleotide polymorphism (SNPs) using adjusted linear regression models and combined using meta-analysis methods. Polygenic risk scores (PRSs) for retinal thickness and AD were generated. Several genetic loci affecting retinal thickness were identified across the genome in accordance with previous reports. The genetic overlap between retinal thickness and dementia, however, was weak and limited to the GCIPL layer; only those observable with all-type dementia cases were considered. Our study does not support the existence of a genetic link between dementia and retinal thickness.

Sections du résumé

BACKGROUND BACKGROUND
Several studies have reported a relationship between retinal thickness and dementia. Therefore, optical coherence tomography (OCT) has been proposed as an early diagnosis method for Alzheimer's disease (AD). In this study, we performed a genome-wide association study (GWAS) aimed at identifying genes associated with retinal nerve fiber layer (RNFL) and ganglion cell inner plexiform layer (GCIPL) thickness assessed by OCT and exploring the relationships between the spectrum of cognitive decline (including AD and non-AD cases) and retinal thickness.
METHODS METHODS
RNFL and GCIPL thickness at the macula were determined using two different OCT devices (Triton and Maestro). These determinations were tested for association with common single nucleotide polymorphism (SNPs) using adjusted linear regression models and combined using meta-analysis methods. Polygenic risk scores (PRSs) for retinal thickness and AD were generated.
RESULTS RESULTS
Several genetic loci affecting retinal thickness were identified across the genome in accordance with previous reports. The genetic overlap between retinal thickness and dementia, however, was weak and limited to the GCIPL layer; only those observable with all-type dementia cases were considered.
CONCLUSIONS CONCLUSIONS
Our study does not support the existence of a genetic link between dementia and retinal thickness.

Identifiants

pubmed: 38365752
doi: 10.1186/s13195-024-01398-8
pii: 10.1186/s13195-024-01398-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

38

Subventions

Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : ACE alzheimer Center Barcelona
ID : Intramural Funding
Organisme : Instituto de Salud Carlos III (ISCIII)
ID : PI19/00335, PI17/01474, AC17/00100, PI19/01301, PI22/01403, PMP22/00022
Organisme : Instituto de Salud Carlos III (ISCIII)
ID : PI19/00335, PI17/01474, AC17/00100, PI19/01301, PI22/01403, PMP22/00022
Organisme : Instituto de Salud Carlos III (ISCIII)
ID : PI19/00335, PI17/01474, AC17/00100, PI19/01301, PI22/01403, PMP22/00022
Organisme : Instituto de Salud Carlos III (ISCIII)
ID : PI19/00335, PI17/01474, AC17/00100, PI19/01301, PI22/01403, PMP22/00022
Organisme : Instituto de Salud Carlos III (ISCIII)
ID : PI19/00335, PI17/01474, AC17/00100, PI19/01301, PI22/01403, PMP22/00022
Organisme : Instituto de Salud Carlos III (ISCIII)
ID : PI19/00335, PI17/01474, AC17/00100, PI19/01301, PI22/01403, PMP22/00022
Organisme : Instituto de Salud Carlos III (ISCIII)
ID : PI19/00335, PI17/01474, AC17/00100, PI19/01301, PI22/01403, PMP22/00022
Organisme : Instituto de Salud Carlos III (ISCIII)
ID : PI19/00335, PI17/01474, AC17/00100, PI19/01301, PI22/01403, PMP22/00022
Organisme : Instituto de Salud Carlos III (ISCIII)
ID : PI19/00335, PI17/01474, AC17/00100, PI19/01301, PI22/01403, PMP22/00022

Informations de copyright

© 2024. The Author(s).

Références

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. Available from: https://pubmed.ncbi.nlm.nih.gov/21514250/ . Cited 2023 Mar 9.
pubmed: 21514250 pmcid: 3312024 doi: 10.1016/j.jalz.2011.03.005
Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8:1–13. Available from: https://pubmed.ncbi.nlm.nih.gov/22265587/ . Cited 2023 Mar 9.
pubmed: 22265587 pmcid: 3266529 doi: 10.1016/j.jalz.2011.10.007
Zetterberg H. Biofluid-based biomarkers for Alzheimer’s disease-related pathologies: An update and synthesis of the literature. Alzheimers Dement. 2022;18:1687–93. Available from: https://pubmed.ncbi.nlm.nih.gov/35213777/ . Cited 2023 Mar 9.
pubmed: 35213777 pmcid: 9514308 doi: 10.1002/alz.12618
Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s disease. Alzheimers Dement. 2021;17:1145–56. Available from: https://pubmed.ncbi.nlm.nih.gov/33491853/ . Cited 2023 Mar 9.
pubmed: 33491853 pmcid: 8359457 doi: 10.1002/alz.12283
Ngolab J, Honma P, Rissman RA. Reflections on the utility of the retina as a biomarker for Alzheimer’s disease: a literature review. Neurol Ther. 2019;8:57–72. Available from: https://pubmed.ncbi.nlm.nih.gov/31833024/ . Cited 2023 Mar 9.
pubmed: 31833024 pmcid: 6908534 doi: 10.1007/s40120-019-00173-4
de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen IE, et al. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores. Nat Commun. 2021;12(1):3417. Available from: https://pubmed.ncbi.nlm.nih.gov/34099642/ . Cited 2023 Mar 9.
pubmed: 34099642 pmcid: 8184987 doi: 10.1038/s41467-021-22491-8
den Haan J, Verbraak FD, Visser PJ, Bouwman FH. Retinal thickness in Alzheimer’s disease: a systematic review and meta-analysis. Alzheimers Dement (Amst). 2017;6:162–70. Available from: https://pubmed.ncbi.nlm.nih.gov/28275698/ . Cited 2023 Mar 9.
doi: 10.1016/j.dadm.2016.12.014
Jaffe GJ, Caprioli J. Optical coherence tomography to detect and manage retinal disease and glaucoma. Am J Ophthalmol. 2004;137:156–69. Available from: https://pubmed.ncbi.nlm.nih.gov/14700659/ . Cited 2023 Mar 9.
pubmed: 14700659 doi: 10.1016/S0002-9394(03)00792-X
Lamirel C, Newman N, Biousse V. The use of optical coherence tomography in neurology. Rev Neurol Dis. 2009;6:E105-120.
pubmed: 20065921
Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer’s disease. Ophthalmology. 1990;97:9–17. Available from: https://pubmed.ncbi.nlm.nih.gov/2314849/ . Cited 2023 Mar 9.
pubmed: 2314849 doi: 10.1016/S0161-6420(90)32621-0
Tas A, Yolcu U, Ilhan A, Gundogan FC. Detection of retinal nerve fibre layer degeneration in patients with Alzheimer’s disease using optical coherence tomography: searching new biomarkers. Acta Ophthalmol. 2015;93:e507. Available from: https://pubmed.ncbi.nlm.nih.gov/25488510/ . Cited 2023 Mar 9.
pubmed: 25488510 doi: 10.1111/aos.12614
Sánchez D, Castilla-Marti M, Rodríguez-Gómez O, Valero S, Piferrer A, Martínez G, et al. Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer’s disease. Sci Rep. 2018;8(1):16345. Available from: https://pubmed.ncbi.nlm.nih.gov/30397251/ . Cited 2023 Mar 9.
pubmed: 30397251 pmcid: 6218495 doi: 10.1038/s41598-018-34577-3
Moon S, Jeon S, Seo SK, Kim DE, Jung NY, Kim SJ, et al. Comparison of retinal structural and neurovascular changes between patients with and without amyloid pathology. J Clin Med. 2023;12(4):1310. Available from: https://pubmed.ncbi.nlm.nih.gov/36835845/ . Cited 2023 Mar 10.
pubmed: 36835845 pmcid: 9964845 doi: 10.3390/jcm12041310
Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022;54:412–36. Available from: https://pubmed.ncbi.nlm.nih.gov/35379992/ . Cited 2022 Dec 1.
pubmed: 35379992 pmcid: 9005347 doi: 10.1038/s41588-022-01024-z
Currant H, Hysi P, Fitzgerald TW, Gharahkhani P, Bonnemaijer PWM, Senabouth A, et al. Genetic variation affects morphological retinal phenotypes extracted from UK Biobank optical coherence tomography images. PLoS Genet. 2021;17(5):e1009497. Available from: https://pubmed.ncbi.nlm.nih.gov/33979322/ . Cited 2022 Dec 1.
pubmed: 33979322 pmcid: 8143408 doi: 10.1371/journal.pgen.1009497
Gao XR, Huang H, Kim H. Genome-wide association analyses identify 139 loci associated with macular thickness in the UK Biobank cohort. Hum Mol Genet. 2019;28:1162–72.
pubmed: 30535121 doi: 10.1093/hmg/ddy422
Currant H, Fitzgerald TW, Patel PJ, Khawaja AP, Webster AR, Mahroo OA, et al. Sub-cellular level resolution of common genetic variation in the photoreceptor layer identifies continuum between rare disease and common variation. PLoS Genet. 2023;19:e1010587. Available from: https://pubmed.ncbi.nlm.nih.gov/36848389/ . Cited 2023 May 15.
pubmed: 36848389 pmcid: 9997913 doi: 10.1371/journal.pgen.1010587
Moreno-Grau S, de Rojas I, Hernández I, Quintela I, Montrreal L, Alegret M, et al. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer’s disease and three causality networks: The GR@ACE project. Alzheimers Dement. 2019;15:1333–47. Available from: https://pubmed.ncbi.nlm.nih.gov/31473137/ . Cited 2022 Dec 1.
pubmed: 31473137 doi: 10.1016/j.jalz.2019.06.4950
Boada M, Tárraga L, Hernández I, Valero S, Alegret M, Ruiz A, et al. Design of a comprehensive Alzheimer’s disease clinic and research center in Spain to meet critical patient and family needs. Alzheimers Dement. 2014;10:409–15. Available from: https://pubmed.ncbi.nlm.nih.gov/24035148/ . Cited 2023 Mar 9.
pubmed: 24035148 doi: 10.1016/j.jalz.2013.03.006
Rodríguez-Gómez O, Abdelnour C, Jessen F, Valero S, Boada M. Influence of sampling and recruitment methods in studies of subjective cognitive decline. J Alzheimers Dis. 2015;48(Suppl 1):S99-107. Available from: https://pubmed.ncbi.nlm.nih.gov/26402087/ . Cited 2023 Mar 9.
pubmed: 26402087 doi: 10.3233/JAD-150189
Rodriguez-Gomez O, Sanabria A, Perez-Cordon A, Sanchez-Ruiz D, Abdelnour C, Valero S, et al. FACEHBI: a prospective study of risk factors, biomarkers and cognition in a cohort of individuals with subjective cognitive decline study. Rationale and research protocols. J Prev Alzheimers Dis. 2017;4:100–8. Available from: https://pubmed.ncbi.nlm.nih.gov/29186280/ . Cited 2023 Mar 9.
pubmed: 29186280
Esteban De Antonio E, Pérez-Cordón A, Gil S, Orellana A, Cano A, Alegret M, et al. BIOFACE: a prospective study of risk factors, cognition, and biomarkers in a cohort of individuals with early-onset mild cognitive impairment study. Rationale and research protocols. J Alzheimers Dis. 2021;83:1233–49. Available from: https://pubmed.ncbi.nlm.nih.gov/34420953/ . Cited 2023 Mar 9.
pubmed: 34420953 pmcid: 8543256 doi: 10.3233/JAD-210254
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 2013.
doi: 10.1176/appi.books.9780890425596
Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250–60. Available from: https://pubmed.ncbi.nlm.nih.gov/8094895/ . Cited 2023 May 5.
pubmed: 8094895 doi: 10.1212/WNL.43.2.250
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100. Available from: https://pubmed.ncbi.nlm.nih.gov/28592453/ . Cited 2023 May 5.
pubmed: 28592453 pmcid: 5496518 doi: 10.1212/WNL.0000000000004058
Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–54. Available from: https://pubmed.ncbi.nlm.nih.gov/9855500/ . Cited 2023 May 5.
pubmed: 9855500 doi: 10.1212/WNL.51.6.1546
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–94. Available from: https://pubmed.ncbi.nlm.nih.gov/15324362/ . Cited 2023 Mar 9.
pubmed: 15324362 doi: 10.1111/j.1365-2796.2004.01388.x
Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60:1385–9. Available from: https://pubmed.ncbi.nlm.nih.gov/14568808/ . Cited 2023 Mar 9.
pubmed: 14568808 doi: 10.1001/archneur.60.10.1385
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–4. Available from: https://pubmed.ncbi.nlm.nih.gov/8232972/ . Cited 2023 Mar 9.
pubmed: 8232972 doi: 10.1212/WNL.43.11.2412-a
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98. Available from: https://pubmed.ncbi.nlm.nih.gov/1202204/ . Cited 2023 Mar 9.
pubmed: 1202204 doi: 10.1016/0022-3956(75)90026-6
Blesa R, Pujol M, Aguilar M, Santacruz P, Bertran-Serra I, Hernández G, et al. Clinical validity of the “mini-mental state” for Spanish speaking communities. Neuropsychologia. 2001;39:1150–7. Available from: https://pubmed.ncbi.nlm.nih.gov/11527552/ . Cited 2023 Mar 9.
pubmed: 11527552 doi: 10.1016/S0028-3932(01)00055-0
Alegret M, Espinosa A, Valero S, Vinyes-Junqué G, Ruiz A, Hernández I, et al. Cut-off scores of a brief neuropsychological battery (NBACE) for Spanish individual adults older than 44 years old. PLoS One. 2013;8(10):e76436. Available from: https://pubmed.ncbi.nlm.nih.gov/24146868/ . Cited 2023 Mar 9.
pubmed: 24146868 pmcid: 3797837 doi: 10.1371/journal.pone.0076436
Alegret M, Espinosa A, Vinyes-Junqué G, Valero S, Hernández I, Tárraga L, et al. Normative data of a brief neuropsychological battery for Spanish individuals older than 49. J Clin Exp Neuropsychol. 2012;34:209–19. Available from: https://pubmed.ncbi.nlm.nih.gov/22149440/ . Cited 2023 Mar 9.
pubmed: 22149440 doi: 10.1080/13803395.2011.630652
Chew EY, Lindblad AS, Clemons T. Summary results and recommendations from the age-related eye disease study. Arch Ophthalmol. 2009;127:1678–9. Available from: https://pubmed.ncbi.nlm.nih.gov/20008727/ . Cited 2023 Mar 9.
pubmed: 20008727 pmcid: 3027407 doi: 10.1001/archophthalmol.2009.312
Bokinni Y, Shah N, Maguire O, Laidlaw DAH. Performance of a computerised visual acuity measurement device in subjects with age-related macular degeneration: comparison with gold standard ETDRS chart measurements. Eye (Lond). 2015;29:1085–91. Available from: https://pubmed.ncbi.nlm.nih.gov/26043703/ . Cited 2023 Mar 9.
pubmed: 26043703 doi: 10.1038/eye.2015.94
Pakrou N, Gray T, Mills R, Landers J, Craig J. Clinical comparison of the Icare tonometer and Goldmann applanation tonometry. J Glaucoma. 2008;17:43–7. Available from: https://pubmed.ncbi.nlm.nih.gov/18303384/ . Cited 2023 Mar 9.
pubmed: 18303384 doi: 10.1097/IJG.0b013e318133fb32
Marquié M, Valero S, Martínez J, Alarcón-Martín E, García-Sánchez A, de Rojas I, et al. Differences in macular vessel density in the superficial plexus across cognitive impairment: the NORFACE cohort. Sci Rep. 2022;12(1):16938. Available from: https://pubmed.ncbi.nlm.nih.gov/36209290/ . Cited 2023 Mar 10.
pubmed: 36209290 pmcid: 9547861 doi: 10.1038/s41598-022-21558-w
Yang Q, Reisman CA, Wang Z, Fukuma Y, Hangai M, Yoshimura N, et al. Automated layer segmentation of macular OCT images using dual-scale gradient information. Opt Express. 2010;18:21293. Available from: https://pubmed.ncbi.nlm.nih.gov/20941025/ . Cited 2023 Mar 9.
pubmed: 20941025 doi: 10.1364/OE.18.021293
Wei T, Simko V. corrplot. 2021. https://github.com/taiyun/corrplot . Available from: https://github.com/taiyun/corrplot . Cited 2022 Dec 1.
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153–60. Available from: https://pubmed.ncbi.nlm.nih.gov/31563865/ . Cited 2022 Dec 2.
pubmed: 31563865 pmcid: 10231495 doi: 10.1136/ebmental-2019-300117
Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7. Available from: https://pubmed.ncbi.nlm.nih.gov/25722852/ . Cited 2022 Dec 2.
pubmed: 25722852 pmcid: 4342193 doi: 10.1186/s13742-015-0047-8
Turner SD. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. J Open Source Softw. 2018;3:731.
doi: 10.21105/joss.00731
Peterson H, Kolberg L, Raudvere U, Kuzmin I, Vilo J. gprofiler2 -- an R package for gene list functional enrichment analysis and namespace conversion toolset g: Profiler. F1000Res. 2020;9:ELIXIR-709. Available from: https://pubmed.ncbi.nlm.nih.gov/33564394/ . Cited 2022 Dec 2.
pubmed: 33564394 pmcid: 7859841 doi: 10.12688/f1000research.24956.2
Majeed A, Marwick B, Yu H, Fadavi H, Tavakoli M. Ophthalmic biomarkers for Alzheimer’s disease: a review. Front Aging Neurosci. 2021;13:720167. Available from: https://pubmed.ncbi.nlm.nih.gov/34566623/ . Cited 2022 Dec 2.
pubmed: 34566623 pmcid: 8461312 doi: 10.3389/fnagi.2021.720167
Sánchez D, Castilla-Marti M, Marquié M, Valero S, Moreno-Grau S, Rodríguez-Gómez O, et al. Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer’s disease in a memory clinic. Sci Rep. 2020;10(1):1580. Available from: https://pubmed.ncbi.nlm.nih.gov/32005868/ . Cited 2023 Mar 9.
pubmed: 32005868 pmcid: 6994670 doi: 10.1038/s41598-020-58399-4
Sekimitsu S, Shweikh Y, Shareef S, Zhao Y, Elze T, Segrè A, et al. Association of retinal optical coherence tomography metrics and polygenic risk scores with cognitive function and future cognitive decline. Br J Ophthalmol. 2023:bjo-2022-322762. Available from: https://pubmed.ncbi.nlm.nih.gov/36990674/ . Cited 2023 May 15.
Seibold LK, Mandava N, Kahook MY. Comparison of retinal nerve fiber layer thickness in normal eyes using time-domain and spectral-domain optical coherence tomography. Am J Ophthalmol. 2010;150(6):807–14. Available from: https://pubmed.ncbi.nlm.nih.gov/20888550/ . Cited 2023 May 5.
pubmed: 20888550 doi: 10.1016/j.ajo.2010.06.024
Fongang B, Sargurupremraj M, Jian X, Mishra A, Damotte V, Bis JC, et al. A meta-analysis of genome-wide association studies identifies new genetic loci associated with all-cause and vascular dementia. bioRxiv. 2022:2022.10.11.509802. Available from: https://www.biorxiv.org/content/10.1101/2022.10.11.509802v1 . Cited 2023 Mar 27.

Auteurs

María Eugenia Sáez (ME)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
Centro Andaluz de Estudios Bioinformáticos (CAEBI), Seville, Spain.

Ainhoa García-Sánchez (A)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Itziar de Rojas (I)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Emilio Alarcón-Martín (E)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Joan Martínez (J)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Amanda Cano (A)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Pablo García-González (P)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Raquel Puerta (R)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Clàudia Olivé (C)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Maria Capdevila (M)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Fernando García-Gutiérrez (F)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Miguel Castilla-Martí (M)

Clínica Oftalmológica Dr. Castilla, Barcelona, Spain.
Vista Alpina Eye Clinic, Visp, Switzerland.

Luis Castilla-Martí (L)

PhD Programme in Surgery and Morphological Sciences, Universitat Autònoma de Barcelona, Barcelona, Spain.
Hôpital ophtalmique Jules-Gonin, Fondation asiles des aveugles, University of Lausanne, Lausanne, Switzerland.

Ana Espinosa (A)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Montserrat Alegret (M)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Mario Ricciardi (M)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Vanesa Pytel (V)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.

Sergi Valero (S)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Lluís Tárraga (L)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Mercè Boada (M)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Agustín Ruiz (A)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain. aruiz@fundacioace.org.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain. aruiz@fundacioace.org.
Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, Texas, USA. aruiz@fundacioace.org.

Marta Marquié (M)

Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.

Classifications MeSH